CSBRMEDIUM SIGNALOPPORTUNITY10-K

CSBR has expanded into data licensing and enhanced its multi-omic dataset capabilities while achieving solid revenue growth and improved cash position.

The company is diversifying beyond traditional research services by monetizing its accumulated data through licensing agreements, which could create higher-margin recurring revenue streams. The removal of previous impairment language around the Lumin platform suggests management confidence in the strategic value of their data assets, positioning CSBR to capitalize on the growing demand for oncology research data.

Comparing 2025-07-23 vs 2024-07-19View on EDGAR →
FINANCIAL ANALYSIS

CSBR demonstrated solid operational performance with revenue growing 13.5% to $56.9 million while reducing R&D expenses by 28.5% to $6.8 million, suggesting improved efficiency. The balance sheet strengthened notably with current assets growing substantially to $22.4 million, providing enhanced financial flexibility. Lower capital expenditures of $389K compared to $836K in the prior year indicate a more asset-light approach as the company focuses on leveraging existing data platforms.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+64%
$13.6M→$22.4M

Current assets grew 64% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-53.5%
$836K→$389K

Capex reduced 53.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

R&D Expense
P&L
-28.5%
$9.5M→$6.8M

R&D spending cut 28.5% — could signal cost discipline or concerning reduction in innovation investment.

Total Assets
Balance Sheet
+23.8%
$26.1M→$32.3M

Asset base grew 23.8% — expansion through organic growth, acquisitions, or capital deployment.

Accounts Receivable
Balance Sheet
+17.9%
$9.5M→$11.2M

Receivables grew 17.9% — monitor days sales outstanding for collection efficiency.

Revenue
P&L
+13.5%
$50.2M→$56.9M

Revenue growing 13.5% — solid top-line momentum, watch margins for quality of growth.

Current Liabilities
Balance Sheet
+10.7%
$21.5M→$23.9M

Current liabilities rose 10.7% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2025-07-23
PRIOR — 2024-07-19
ADDED
Data Licenses We offer access to certain PDX model data via licensing agreements.
As our platform has been expanded over time with the collection of models and the enhancement of their characterization, we have developed a robust multi-omic dataset with substantial potential for both drug discovery and development.
This dataset serves as a vital resource for both our pharmaceutical and biotechnology customer who gain access to model-specific data and further their research via licensed access.
Software As A Service (SaaS) Business Our SaaS business is centered around our proprietary software platform and data tool, Lumin Bioinformatics ("Lumin"), which contains comprehensive information derived from our research services and clinical studies and is sold to customers on an annual subscription basis.
For the fiscal year ended April 30, 2025, revenues from our products and services totaled approximately $56.9 million, an increase of approximately 14% from the previous year.
The global oncology drug market is estimated to be as high as $223 billion in 2024 with continued projected growth.
Research and Development For the fiscal years ended April 30, 2025 and 2024, we spent approximately $6.8 million and $9.5 million, respectively, to further develop our platforms.
Human Capital Resources As of July 15, 2025, we had 213 full-time employees, including 93 with doctoral or other advanced degrees.
Of our workforce, 159 employees are engaged in research and development and laboratory operations, 32 employees are engaged in sales and marketing, and 22 employees are engaged in finance and administration.
For the fiscal year ended April 30, 2025, the Company had net income of approximately $4.7 million, an accumulated deficit of approximately $79.9 million, and a cash balance of $9.8 million.
REMOVED
Software As A Service (SaaS) Business Our SaaS business, launched during the fiscal year ended April 30, 2021, is centered around our proprietary software platform and data tool, Lumin Bioinformatics ("Lumin"), which contains comprehensive information derived from our research services and clinical studies and is sold to customers on an annual subscription basis.
During the fiscal year ended April 30, 2023, we recorded an impairment charge for the capitalized software development costs of Lumin related to return on investment guidelines.
However, we continue to maintain the Lumin platform and sell subscriptions as part of our product offerings as the Lumin data is an integral part of the Company s long term strategy and value proposition.
For the fiscal year ended April 30, 2024, revenues from our products and services totaled approximately $50.1 million, a decrease of approximately 7% from the previous year.
The global oncology drug market is estimated to be as high as $223 billion in 2023.
Research and Development For the fiscal years ended April 30, 2024 and 2023, we spent approximately $9.5 million and $11.5 million, respectively, to further develop our platforms.
Human Capital Resources As of July 15, 2024, we had 210 full-time employees, including 96 with doctoral or other advanced degrees.
Of our workforce, 160 employees are engaged in research and development and laboratory operations, 30 employees are engaged in sales and marketing, and 20 employees are engaged in finance and administration.
These conditions raise a substantial doubt about our ability to continue as a going concern.
6 For the fiscal year ended April 30, 2024, the Company had a net loss of approximately $7.3 million and used cash flows in operations of approximately $6.1 million.
MORE OPPORTUNITY SIGNALS
ABTHIGHAbbott announced a major strategic acquisition of Exact Sciences Corporation to ...
2026-02-20
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →